A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Status: Closed to Accrual

• Condition: Hepatocellular carcinoma
• Intervention:
  • Drug: Pembrolizumab
  • Drug: Y90 radioembolization
• Phase: Pilot study

For full description, see www.clinicaltrials.gov. (Study #NCT03099564).

Read a news release about this trial.

Funding for this study is provided by Merck Sharp & Dohme Corp.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.